Fauna Bio

Executive Summary

Fauna Bio is an AI-driven drug discovery company leveraging comparative genomics and unique biological data from extreme mammals to identify novel therapeutic targets. Its Convergence™ platform analyzes genetic data from species like hibernating ground squirrels and regenerative spiny mice to translate natural protective mechanisms into human medicines. The company focuses on metabolic diseases, fibrosis, and regeneration, with a major obesity collaboration with Eli Lilly. In pre-clinical stage and founded in 2018, Fauna Bio's platform offers a differentiated approach to target discovery by exploiting evolutionary adaptations. The partnership with Lilly validates the technology and provides potential for near-term milestones. However, the company is private and early-stage, with no disclosed funding or valuation, indicating high risk. Its success hinges on advancing its pipeline and securing additional partnerships or financing.

Upcoming Catalysts (preview)

• 2025Progress update on Eli Lilly obesity collaboration50% success
• 2025Series B or C funding round announcement60% success
• 2026Preclinical proof-of-concept data in fibrosis or metabolic disease40% success